Your browser doesn't support javascript.
loading
Modulation of the proteostasis network promotes tumor resistance to oncogenic KRAS inhibitors.
Lv, Xiangdong; Lu, Xuan; Cao, Jin; Luo, Qin; Ding, Yao; Peng, Fanglue; Pataer, Apar; Lu, Dong; Han, Dong; Malmberg, Eric; Chan, Doug W; Wang, Xiaoran; Savage, Sara R; Mao, Sufeng; Yu, Jingjing; Peng, Fei; Yan, Liang; Meng, Huan; Maneix, Laure; Han, Yumin; Chen, Yiwen; Yao, Wantong; Chang, Eric C; Catic, Andre; Lin, Xia; Miles, George; Huang, Pengxiang; Sun, Zheng; Burt, Bryan; Wang, Huamin; Wang, Jin; Yao, Qizhi Cathy; Zhang, Bing; Roth, Jack A; O'Malley, Bert W; Ellis, Matthew J; Rimawi, Mothaffar F; Ying, Haoqiang; Chen, Xi.
Afiliación
  • Lv X; Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX 77030, USA.
  • Lu X; Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX 77030, USA.
  • Cao J; Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA.
  • Luo Q; Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX 77030, USA.
  • Ding Y; Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX 77030, USA.
  • Peng F; Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA.
  • Pataer A; Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX 77030, USA.
  • Lu D; Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX 77030, USA.
  • Han D; Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA.
  • Malmberg E; Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX 77030, USA.
  • Chan DW; Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX 77030, USA.
  • Wang X; Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA.
  • Savage SR; Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX 77030, USA.
  • Mao S; Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX 77030, USA.
  • Yu J; Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA.
  • Peng F; Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX 77030, USA.
  • Yan L; Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX 77030, USA.
  • Meng H; Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA.
  • Maneix L; Department of Thoracic and Cardiovascular Surgery, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Han Y; Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX 77030, USA.
  • Chen Y; Department of Pharmacology and Chemical Biology, Baylor College of Medicine, Houston, TX 77030, USA.
  • Yao W; Center for Drug Discovery, Baylor College of Medicine, Houston, TX 77030, USA.
  • Chang EC; Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX 77030, USA.
  • Catic A; Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX 77030, USA.
  • Lin X; Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA.
  • Miles G; Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX 77030, USA.
  • Huang P; Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX 77030, USA.
  • Sun Z; Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA.
  • Burt B; Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX 77030, USA.
  • Wang H; Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX 77030, USA.
  • Wang J; Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA.
  • Yao QC; Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX 77030, USA.
  • Zhang B; Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX 77030, USA.
  • Roth JA; Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA.
  • O'Malley BW; Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX 77030, USA.
  • Ellis MJ; Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA.
  • Rimawi MF; Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX 77030, USA.
  • Ying H; Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX 77030, USA.
  • Chen X; Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX 77030, USA.
Science ; 381(6662): eabn4180, 2023 09 08.
Article en En | MEDLINE | ID: mdl-37676964
ABSTRACT
Despite substantial advances in targeting mutant KRAS, tumor resistance to KRAS inhibitors (KRASi) remains a major barrier to progress. Here, we report proteostasis reprogramming as a key convergence point of multiple KRASi-resistance mechanisms. Inactivation of oncogenic KRAS down-regulated both the heat shock response and the inositol-requiring enzyme 1α (IRE1α) branch of the unfolded protein response, causing severe proteostasis disturbances. However, IRE1α was selectively reactivated in an ER stress-independent manner in acquired KRASi-resistant tumors, restoring proteostasis. Oncogenic KRAS promoted IRE1α protein stability through extracellular signal-regulated kinase (ERK)-dependent phosphorylation of IRE1α, leading to IRE1α disassociation from 3-hydroxy-3-methylglutaryl reductase degradation (HRD1) E3-ligase. In KRASi-resistant tumors, both reactivated ERK and hyperactivated AKT restored IRE1α phosphorylation and stability. Suppression of IRE1α overcame resistance to KRASi. This study reveals a druggable mechanism that leads to proteostasis reprogramming and facilitates KRASi resistance.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Proteínas Proto-Oncogénicas p21(ras) / Resistencia a Antineoplásicos / Quinasas MAP Reguladas por Señal Extracelular / Endorribonucleasas / Inhibidores Enzimáticos / Factores de Transcripción del Choque Térmico / Proteostasis / Neoplasias / Antineoplásicos Límite: Humans Idioma: En Revista: Science Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Proteínas Proto-Oncogénicas p21(ras) / Resistencia a Antineoplásicos / Quinasas MAP Reguladas por Señal Extracelular / Endorribonucleasas / Inhibidores Enzimáticos / Factores de Transcripción del Choque Térmico / Proteostasis / Neoplasias / Antineoplásicos Límite: Humans Idioma: En Revista: Science Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos